Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164,729 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Song Y, Zhang B, Xin D, Kou X, Tan Z, Zhang S, Sun M, Zhou J, Fan M, Zhang M, Song Y, Li S, Yuan Y, Zhuang W, Zhang J, Zhang L, Jiang H, Gu K, Ye H, Ke Y, Li J, Wang Q, Zhu J, Huang J; ASTRUM-007 investigators. Song Y, et al. Among authors: zhang l, zhang m, zhang b, zhang s, zhang j. Nat Med. 2023 Feb;29(2):473-482. doi: 10.1038/s41591-022-02179-2. Epub 2023 Feb 2. Nat Med. 2023. PMID: 36732627 Free PMC article. Clinical Trial.
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial.
Song Y, Li N, Li Q, Liang X, Zhang S, Fan Q, Yin X, Zhuang Z, Liu Y, Zhang J, Kou X, Zhong H, Wang X, Dou Y, Huang J. Song Y, et al. Among authors: zhang s, zhang j. J Immunother Cancer. 2020 Oct;8(2):e001279. doi: 10.1136/jitc-2020-001279. J Immunother Cancer. 2020. PMID: 33060149 Free PMC article. Clinical Trial.
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial.
Luo H, Lu J, Bai Y, Mao T, Wang J, Fan Q, Zhang Y, Zhao K, Chen Z, Gao S, Li J, Fu Z, Gu K, Liu Z, Wu L, Zhang X, Feng J, Niu Z, Ba Y, Zhang H, Liu Y, Zhang L, Min X, Huang J, Cheng Y, Wang D, Shen Y, Yang Q, Zou J, Xu RH; ESCORT-1st Investigators. Luo H, et al. Among authors: zhang l, zhang x, zhang h, zhang y. JAMA. 2021 Sep 14;326(10):916-925. doi: 10.1001/jama.2021.12836. JAMA. 2021. PMID: 34519801 Free PMC article. Clinical Trial.
Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, Ogata T, Kawakami H, Hsu CH, Adenis A, El Hajbi F, Di Bartolomeo M, Braghiroli MI, Holtved E, Ostoich SA, Kim HR, Ueno M, Mansoor W, Yang WC, Liu T, Bridgewater J, Makino T, Xynos I, Liu X, Lei M, Kondo K, Patel A, Gricar J, Chau I, Kitagawa Y; CheckMate 648 Trial Investigators. Doki Y, et al. N Engl J Med. 2022 Feb 3;386(5):449-462. doi: 10.1056/NEJMoa2111380. N Engl J Med. 2022. PMID: 35108470 Clinical Trial.
Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2).
Xu J, Li Y, Fan Q, Shu Y, Yang L, Cui T, Gu K, Tao M, Wang X, Cui C, Xu N, Xiao J, Gao Q, Liu Y, Zhang T, Bai Y, Li W, Zhang Y, Dai G, Ma D, Zhang J, Bai C, Huang Y, Liao W, Wu L, Chen X, Yang Y, Wang J, Ji S, Zhou H, Wang Y, Ma Z, Wang Y, Peng B, Sun J, Mancao C. Xu J, et al. Among authors: zhang t, zhang j, zhang y. Nat Commun. 2022 Feb 14;13(1):857. doi: 10.1038/s41467-022-28408-3. Nat Commun. 2022. PMID: 35165274 Free PMC article. Clinical Trial.
Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma: a randomized, multicenter phase II trial.
Lu Z, Zhang Y, Fan Q, Pan Y, Jiang D, Lu P, Zhang J, Yuan X, Feng J, Yang S, Yue W, Zhao L, Xu Y, Luo J, Shen L. Lu Z, et al. Among authors: zhang j, zhang y. Innovation (Camb). 2022 Apr 4;3(3):100239. doi: 10.1016/j.xinn.2022.100239. eCollection 2022 May 10. Innovation (Camb). 2022. PMID: 35509869 Free PMC article.
PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study.
Chen M, Wang Z, Liu Z, Deng T, Wang X, Chang Z, Zhang Q, Yang W, Liu N, Ji Z, Zhang X, Wang X, Peng Z, Li Y, Cao Y, Jin X, Lu H, Qu H, Tang Y, Xu C, Fang W, Zhang H, Yan D, Wang L, Li J, Zhang J, Wang Q, Xue L, Yin F, Han G, Cheng Z, Liu Q, Jin Y, Zhang Y, Li L, Cao B, Yao Y, Chen Z, Zou J, Ying J, Wei Q, Tian T, Zhao W, Li L, Zhang T, Song F, Ba YE, Li N, Gao H, Ji Y, Bao L, Zhao X, Cai J, Yuan Z, Shen L, Li J. Chen M, et al. Among authors: zhang q, zhang t, zhang j, zhang x, zhang h, zhang y. JCO Precis Oncol. 2023 Mar;7:e2200463. doi: 10.1200/PO.22.00463. JCO Precis Oncol. 2023. PMID: 36996375 Free PMC article.
Phase 2 Study of the PD-1 Inhibitor Serplulimab plus the Bevacizumab Biosimilar HLX04 in Patients with Previously Treated Advanced Hepatocellular Carcinoma.
Ren Z, Shao G, Shen J, Zhang L, Zhu X, Fang W, Sun G, Bai Y, Wu J, Liu L, Yuan Y, Zhang J, Li Z, Zhang L, Yin T, Wu J, Hou X, Wang Q, Zhu J, Fan J. Ren Z, et al. Among authors: zhang l, zhang j. Liver Cancer. 2022 Aug 30;12(2):116-128. doi: 10.1159/000526638. eCollection 2023 Jun. Liver Cancer. 2022. PMID: 37325495 Free PMC article.
164,729 results
You have reached the last available page of results. Please see the User Guide for more information.